Chargement en cours...
Targeting the Complement Pathway as a Therapeutic Strategy in Lung Cancer
Lung cancer is the leading cause of cancer death in men and women. Lung adenocarcinoma (LUAD), represents approximately 40% of all lung cancer cases. Advances in recent years, such as the identification of oncogenes and the use of immunotherapies, have changed the treatment of LUAD. Yet survival rat...
Enregistré dans:
| Publié dans: | Front Immunol |
|---|---|
| Auteurs principaux: | , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Frontiers Media S.A.
2019
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6522855/ https://ncbi.nlm.nih.gov/pubmed/31134065 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2019.00954 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|